Modulation of cancer prevention by social stress

社会压力对癌症预防的调节

• 批准号: 7809021
• 负责人: Hildegard M. Schuller
• 金额: $ 50万
• 依托单位: UNIVERSITY OF TENNESSEE KNOXVILLE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7809021
• 关键词: Address; Adenocarcinoma; Adenocarcinoma Cell; Adenylate Cyclase; Adrenergic Agents; Adverse effects; African American; Agonist; Aminobutyric Acids; Antineoplastic Agents; Area; Behavior; Behavioral; Breast; Cell Line; Cells; Chronic; Clinical Trials; Colon Adenocarcinoma; Colon Carcinoma; Cyclic AMP; Data; Development; Disease; Effectiveness; Epidermal Growth Factor; Epinephrine; Failure; Foundations; Glucocorticoids; Hand; Health behavior; Histopathology; Hormones; Human; Human Cell Line; Hydrocortisone; Immunohistochemistry; In Vitro; Incidence; Laboratory Animals; Lead; Lung; Lung Adenocarcinoma; Malignant Neoplasms; Malignant neoplasm of ovary; Measurement; Mus; Mutation; Neurotransmitters; Nicotine; Nicotinic Receptors; Non-Steroidal Anti-Inflammatory Agents; Norepinephrine; Nude Mice; Ovary; PTGS2 gene; Pancreatic Ductal Adenocarcinoma; Physiological; Preclinical Testing; Prevention; Prevention strategy; Prevention therapy; Preventive; Production; Prostate; Psychological Stress; Reporting; Role; Signal Transduction; Stomach; Stress; System; Testing; Time; Vascular Endothelial Growth Factors; Western Blotting; Xenograft procedure; adrenergic; base; beta-adrenergic receptor; cancer cell; cancer prevention; celecoxib; dietary supplements; drug testing; gamma-Aminobutyric Acid; improved; in vivo; inhibitor/antagonist; low socioeconomic status; lung cancer prevention; molecular marker; mortality; non-genomic; novel; receptor; response; social stress; tumor progression

DESCRIPTION (provided by applicant): This application addresses broad Challenge Area (01) Behavior, Behavioral Change, and Prevention and the specific Challenge Topic, 01-CA-103: The Role of Health Behaviors in Cancer Prevention. Chronic psychological stress and the resulting systemic increase in stress neurotransmitters noradrenaline and adrenaline and the glucocorticoid stress hormone cortisol enhance vulnerability to numerous diseases. However, the effects of stress on the prevention of cancer has not been studied to date. We have shown that two of the most common and most deadly cancers, small airway-derived pulmonary adenocarcinoma (PAC) and pancreatic ductal adenocarcinoma (PDAC) are stimulated in vitro and in vivo by cAMP-dependent signaling downstream of beta-adrenergic receptors (b-ARs) and that glucocorticoids stimulate these cells by increasing cAMP signaling. These findings suggest that a stress-related increase in noradrenaline and adrenaline (that are agonists for b-ARs) and cortisol will stimulate the development and progression of these cancers, thus counteracting the effects of cancer preventive agents. The disappointing and as yet poorly understood disconnect between promising results of preclinical testing and failure of these agents in clinical trials may thus be caused by the absence of stress in carefully maintained systems for the testing of anti- cancer drugs in vitro and in laboratory animals. On the other hand, we have shown in PAC and PDAC cells in vitro that the stimulating cAMP signaling downstream of b-ARs is inhibited by the neurotransmitter g- aminobutyric acid (GABA) that inhibits the activation of adenylyl cyclase. In addition, we have shown in mouse xenografts from PDAC and PAC that GABA reverses the cancer promoting effects of nicotine, which include a nicotinic receptor-induced systemic increase in noradrenaline and adrenaline. Based on these data we will test the hypotheses in xenografts of two human PAC and two PDAC cell that the development and progression of PAC and PDAC is stimulated by psychological stress, decreases the responsiveness to cancer prevention by a non-steroidal anti-inflammatory agent, and that treatment with GABA reverses these effects. We will use nude mice subjected to chronic social stress and assess the impact of this condition on cancer prevention by daily measurements of xenograft size as well as the quantitative determination of molecular markers by real-time PCR and Western blotting accompanied by histopathology and immunohistochemistry. Specific Aim 1: To test the hypothesis that psychological stress stimulates the development and progression of PDAC and PAC. Specific Aim 2: To test the hypothesis that psychological stress reduces the cancer preventive effects of the COX-2 inhibitor celecoxib on PDAC and PAC xenografts. Specific Aim 3: To test the hypothesis that treatment with GABA reverses the effects of psychological stress in mice without celecoxib prevention. Specific Aim 4: To test the hypothesis that GABA reverses the adverse effects of psychological stress on cancer prevention with celecoxib. Data generated by this 2-year project have a high chance to significantly improve the effectiveness of PAC and PDAC prevention and also provide a foundation for improved prevention of cancer of the colon, prostate, breast, stomach and ovary, all of which are stimulated by beta-adrenergic signaling. This application addresses broad Challenge Area (01) Behavior, Behavioral Change, and Prevention and the specific Challenge Topic, 01-CA-103: The Role of Health Behaviors in Cancer Prevention. Chronic psychological stress and the resulting systemic increase in stress neurotransmitters noradrenaline and adrenaline and the glucocorticoid stress hormone cortisol enhance vulnerability to numerous diseases. Low socioeconomic status, which creates chronic psychological stress and is particularly prevalent in African Americans, is associated with a significantly higher incidence and mortality of all cancers. However, the negative modulation of cancer prevention by psychological stress has not been studied to date and no information exists as to how such negative effects can be overcome. The current project will test the hypotheses in mice with xenografts of cell lines from human lung adenocarcinomas and pancreatic ductal adenocarcinomas that the development and progression of these cancers is stimulated by psychological stress, decreases the responsiveness to cancer prevention by a non steroidal anti-inflammatory agent, and that treatment with gamma-aminobutyric acid (GABA) reverses these effects. Data generated by this 2-year project will rapidly improve the prevention of lung cancer and panreatic cancer and lay the foundation for the rapid development of more successful prevention and therapy of cancer of the colon, prostate, breast, stomach and ovary.

描述（由申请人提供）：本申请涉及广泛的挑战领域（01）行为，行为变化和预防以及特定的挑战主题，01-CA-103：健康行为在癌症预防中的作用。慢性心理压力和由此产生的压力神经递质去甲肾上腺素和肾上腺素以及糖皮质激素应激激素皮质醇的全身性增加了对许多疾病的脆弱性。然而，压力对预防癌症的影响迄今尚未得到研究。我们已经证明，两种最常见和最致命的癌症，小气道来源的肺腺癌（PAC）和胰腺导管腺癌（PDAC）在体外和体内受到β-肾上腺素能受体（b-AR）下游cAMP依赖性信号传导的刺激，糖皮质激素通过增加cAMP信号传导刺激这些细胞。这些发现表明，与压力相关的去甲肾上腺素和肾上腺素（b-AR的激动剂）和皮质醇的增加将刺激这些癌症的发展和进展，从而抵消癌症预防剂的作用。因此，临床前试验的有希望的结果与这些药物在临床试验中的失败之间令人失望且尚未得到充分理解的脱节可能是由于在用于体外和实验室动物中测试抗癌药物的精心维护的系统中缺乏压力造成的。另一方面，我们已经在体外PAC和PDAC细胞中表明，b-AR下游的刺激性cAMP信号传导被神经递质γ-氨基丁酸（GABA）抑制，该神经递质γ-氨基丁酸（GABA）抑制腺苷酸环化酶的活化。此外，我们在PDAC和PAC的小鼠异种移植物中显示，GABA逆转尼古丁的促癌作用，包括烟碱受体诱导的去甲肾上腺素和肾上腺素全身性增加。基于这些数据，我们将测试两个人PAC和两个PDAC细胞的异种移植物中的假设，即PAC和PDAC的发展和进展受到心理应激的刺激，降低了对非甾体抗炎药预防癌症的反应性，并且用GABA治疗逆转了这些作用。我们将使用裸鼠进行慢性社会压力和评估这种情况下对癌症预防的影响，每天测量异种移植物的大小，以及定量测定分子标记物的实时PCR和蛋白质印迹伴随组织病理学和免疫组织化学。具体目标1：检验心理应激刺激PDAC和PAC的发展和进展的假设。具体目标二：检验心理压力降低考克斯-2抑制剂塞来昔布对PDAC和PAC异种移植物的癌症预防作用的假设。具体目的3：检验GABA治疗逆转未使用塞来昔布预防的小鼠的心理应激效应的假设。具体目标4：验证GABA逆转心理应激对塞来昔布预防癌症的不良影响的假设。这个为期2年的项目产生的数据很有可能显着提高PAC和PDAC预防的有效性，并为改善结肠癌，前列腺癌，乳腺癌，胃癌和卵巢癌的预防提供基础，所有这些都是由β-肾上腺素能信号刺激的。此应用程序解决了广泛的挑战领域（01）行为，行为改变和预防和特定的挑战主题，01-CA-103：健康行为在癌症预防中的作用。慢性心理压力和由此产生的压力神经递质去甲肾上腺素和肾上腺素以及糖皮质激素应激激素皮质醇的全身性增加了对许多疾病的脆弱性。低社会经济地位会产生慢性心理压力，在非裔美国人中尤其普遍，与所有癌症的发病率和死亡率显着较高有关。然而，迄今为止尚未研究心理压力对癌症预防的负面影响，也没有关于如何克服这种负面影响的信息。目前的项目将在小鼠中测试来自人肺腺癌和胰腺导管腺癌的细胞系异种移植物的假设，即这些癌症的发展和进展受到心理压力的刺激，降低了对非甾体抗炎药预防癌症的反应性，并且用γ-氨基丁酸（GABA）治疗可以逆转这些作用。这个为期2年的项目产生的数据将迅速改善肺癌和胰腺癌的预防，并为结肠癌、前列腺癌、乳腺癌、胃癌和卵巢癌的更成功预防和治疗的快速发展奠定基础。